ClinicalTrials.gg
CompletedNCT02066792Updated Jun 15, 2026Results posted

Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder

An Early Phase 1 interventional study of D-Cycloserine and Placebo in Social Anxiety Disorder, sponsored by Jasper A. Smits. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Jasper A. Smits · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 187 studies in Phobia, Social with a site in United States — 23 open to participants now, 29 under way, 1 of them phase 3. Phobia, Social · United States.

Enrollment
46th of 178
152 · median 64
Started
2014
with 10 others
Phase 1
10 of 187
1 open now
Registered
70th of 187
by date

Among the 187 studies in Phobia, Social with a site in United States, this one is the 46th largest by enrollment of the 178 interventional ones that give a count, is one of 11 that started in 2014, is one of 10 in phase 1, and was the 70th registered.

Phobia, Social

368 studies on the registry are indexed under Phobia, Social; 59 are open to participants now.

Browse Phobia, Social studies →

Open to participants now

23 of the 187 studies in Phobia, Social with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Phobia, Social studies recruiting now, 10 (22%) set no upper age limit and 34 (74%) stop at 75 or younger; 14 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Phobia, Social with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to examine the efficacy of 50 mg of d-cycloserine in comparison to placebo (a pill containing no medication) for improving the effectiveness of cognitive-behavioral therapy (CBT) in reducing symptoms associated with social anxiety disorder. In addition, the study will examine whether the effectiveness of d-cycloserine depends on the timing of the pill administration (i.e., 1- hour before the session or immediately after the session) as well as the success of the CBT therapy sessions. The investigators hypothesize that the tailored post-session DCS administration condition will outperform the other conditions (pre-session DCS, placebo, and non-tailored post-session DCS). This will be evidenced by short- and long-term improvements in social anxiety severity.

03

Conditions studied

  • Social Anxiety Disorder

Browse trials for

Keywords

  • Social Phobia
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female outpatients > 18 years of age with a primary psychiatric diagnosis (designated by the patient as the most important source of current distress) of social anxiety disorder as defined by criteria.
  • A total score > 60 on the LSAS.
  • Physical examination and laboratory findings without abnormalities.
  • Willingness and ability to participate in the process and comply with the requirements of the study protocol.

Exclusion criteria

Exclusion Criteria:

  • A lifetime history of bipolar disorder, schizophrenia, psychosis, delusional disorders or obsessive-compulsive disorder; an eating disorder in the past 6 months; organic brain syndrome, mental retardation or other cognitive dysfunction that could interfere with capacity to engage in therapy; a history of substance or alcohol abuse or dependence (other than nicotine) in the last 6 months or otherwise unable to commit to refraining from alcohol use during the acute period of study participation.
  • PTSD within the past 6 months. Entry of patients with other mood or anxiety disorders will be permitted if the SAD is judged to be the predominant disorder, in order to increase accrual of a sample. Patients with significant suicidal ideation (MADRS item 10 score > 3) or who have enacted suicidal behaviors within 6 months prior to intake will be excluded from study participation and referred for appropriate clinical intervention.
  • Patients must be off concurrent psychotropic medication (e.g., antidepressants, anxiolytics, beta blockers) for at least 2 weeks prior to initiation of randomized treatment.
  • Significant personality dysfunction likely to interfere with study participation.
  • Serious medical illness or instability for which hospitalization may be likely within the next year.
  • Patients with a current or past history of seizures.
  • Pregnant women, lactating women, and women of who are not using medically accepted forms of (e.g., IUD, oral contraceptives, barrier devices, condoms and foam, or implanted progesterone rods stabilized for at least 3 months).
  • Any concurrent psychotherapy initiated within 3 months of baseline, or ongoing psychotherapy of any duration directed specifically toward treatment of the SAD is excluded. Prohibited psychotherapy includes CBT or psychodynamic therapy focusing on exploring specific, dynamic causes of the phobic symptomatology and providing management skills. General supportive therapy initiated > 3 months prior is acceptable.
  • Prior non-response to adequately-delivered exposure (i.e., as defined by the patient's report of receiving specific and regular exposure assignments as part of a previous treatment).
  • Patients with a history of head trauma causing loss of consciousness, seizure or ongoing cognitive impairment. Current use of isoniazid or ethionamide compounds
  • Insufficient command of the English language
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    Tailored Post-Session DCS

    Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs/placebo after the session). The type of pill (i.e. dcs vs. placebo) will be determined after the session.

    Drug: D-Cycloserine · Drug: Placebo · Behavioral: Cognitive Behavioral Therapy

  • Active comparator
    Pre-Session DCS

    Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one dcs before and one placebo after the session).

    Drug: D-Cycloserine · Drug: Placebo · Behavioral: Cognitive Behavioral Therapy

  • Placebo comparator
    Placebo

    Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one placebo after the session).

    Drug: Placebo · Behavioral: Cognitive Behavioral Therapy

  • Active comparator
    Non-Tailored Post-Session DCS

    Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs after the session).

    Drug: D-Cycloserine · Drug: Placebo · Behavioral: Cognitive Behavioral Therapy

Interventions

  • DrugCycloserineStudies of CycloserineCycloserine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    D-cycloserine is a medication thought to be associated with fear extinction.

    Also known as: D-cycloserine, DCS

  • DrugPlacebo

    Sugar pill

  • BehavioralCognitive Behavioral Therapy

    This will be a 5-session version of a group CBT protocol with 4-6 patients and 2 therapists per group emphasizing repeated exposure practices. Session 1 involves an introduction and orientation to the CBT model. Sessions 2-5 emphasize repeated exposure tasks, which consist of role-play activities to confront fearful situations in a group setting while disputing cognitive distortions (coupled with the fading of safety behaviors). At the conclusion of each exposure session, patients will be encouraged to continue to apply home-practice strategies (such as giving speeches in front of a mirror). Continued practice of the interventions will be considered part of treatment, and patients will be asked to refrain from alternative treatment for four weeks following completion of the last treatment session.

    Also known as: CBT

06

What researchers measure

Primary outcomes

  1. Social Anxiety Symptom Severity

    The main outcome was a composite Z-score from the Liebowitz Social Anxiety Scale (LSAS) and the Social Phobic Disorders Severity and Change Form (SPD-SC Form). "The Composite Z-score of the LSAS and SPD-SC Form indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population. Negative numbers indicate values lower symptom severity and positive numbers indicate higher symptom severity. The LSAS is a 24-item scale that measures fear and avoidance in social and performance situations within the last week, using 0 (no fear/never avoids) to 3 (severe fear/usually avoids) scale. LSAS scores range from 0-144 with higher scores indicated worse outcomes. The SPD-S is the Clinical Global Impression Scale27 adapted for SAD, which instructs evaluators to use a 7-point scale (1=normal, not at all ill; 7=among the most extremely ill patients) to index the severity of social anxiety.

    Time frame: Assessments took place at multiple time points from baseline to 3-month follow-up. The three-month is reported

07

Results

Posted Jun 9, 2020

Participant flow

Participant flow — Overall Study
MilestoneTailored Post-Session DCSPre-Session DCSPlaceboNon-Tailored Post-Session DCS
Started40383836
Completed33333027
Not completed7589

Outcome measures

PrimarySocial Anxiety Symptom Severity

The main outcome was a composite Z-score from the Liebowitz Social Anxiety Scale (LSAS) and the Social Phobic Disorders Severity and Change Form (SPD-SC Form). "The Composite Z-score of the LSAS and SPD-SC Form indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population. Negative numbers indicate values lower symptom severity and positive numbers indicate higher symptom severity. The LSAS is a 24-item scale that measures fear and avoidance in social and performance situations within the last week, using 0 (no fear/never avoids) to 3 (severe fear/usually avoids) scale. LSAS scores range from 0-144 with higher scores indicated worse outcomes. The SPD-S is the Clinical Global Impression Scale27 adapted for SAD, which instructs evaluators to use a 7-point scale (1=normal, not at all ill; 7=among the most extremely ill patients) to index the severity of social anxiety.

Time frame:
Assessments took place at multiple time points from baseline to 3-month follow-up. The three-month is reported
Reported as:
Mean · score on a scale
Social Anxiety Symptom Severity
score on a scaleTailored Post-Session DCSPre-Session DCSPlaceboNon-Tailored Post-Session DCS
Social Anxiety Symptom Severity-.46 ± .13-.90 ± .13-.39 ± .14-.88 ± .14
Statistical analysis
  • Pre-Session DCS vs Placebo · Mixed Models Analysis · p = <.001 (two-sided) · Mean difference (final values): -.51 · 95% CI -.81 to -.21Four level multivariate MLM with measures nested within time, which was nested within subjects, who were nested within treatment cohort.
  • Tailored Post-Session DCS vs Placebo · Mixed Models Analysis · p = .635 (Two-sided) · Mean difference (final values): -.07 · 95% CI -.37 to .23Four level multivariate MLM with measures nested within time, which was nested within subjects, who were nested within treatment cohort.
  • Placebo vs Non-Tailored Post-Session DCS · Mixed Models Analysis · p = .002 · Mean difference (final values): -.49 · 95% CI -.80 to -.18Four level multivariate MLM with measures nested within time, which was nested within subjects, who were nested within treatment cohort.
  • Tailored Post-Session DCS vs Pre-Session DCS · Mixed Models Analysis · p = .004 · Mean difference (final values): -.44 · 95% CI -.73 to -.14Four level multivariate MLM with measures nested within time, which was nested within subjects, who were nested within treatment cohort.
  • Tailored Post-Session DCS vs Non-Tailored Post-Session DCS · Mixed Models Analysis · p = .008 · Mean difference (final values): -.41 · 95% CI -.72 to -.11Four level multivariate MLM with measures nested within time, which was nested within subjects, who were nested within treatment cohort.

Adverse events

Collected over Data for adverse events was collected at each assessment point over the course of the study (e.g., in-person screening, baseline appointment, sessions 1-5, and the 1-week, 1-month, and 3-month follow-ups).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tailored Post-Session DCS0/40 (0%)0/40 (0%)0/40 (0%)
Pre-Session DCS0/38 (0%)0/38 (0%)0/38 (0%)
Placebo0/38 (0%)1/38 (2.6%)0/38 (0%)
Non-Tailored Post-Session DCS0/36 (0%)0/36 (0%)0/36 (0%)
Most frequent serious events
Most frequent serious events
EventTailored Post-Session DCSPre-Session DCSPlaceboNon-Tailored Post-Session DCS
Serious Adverse EventPsychiatric disorders0/400/381/380/36

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Tailored Post-Session DCSPre-Session DCSPlaceboNon-Tailored Post-Session DCSTotal
<=18 years00000
Between 18 and 65 years40383836152
>=65 years00000
Age, Continuous
Age, Continuous(Years)Tailored Post-Session DCSPre-Session DCSPlaceboNon-Tailored Post-Session DCSTotal
Mean30.78 ± 9.8829.73 ± 10.4228.76 ± 11.8127.54 ± 8.2929.20 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Tailored Post-Session DCSPre-Session DCSPlaceboNon-Tailored Post-Session DCSTotal
Female2422182185
Male1616201567
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tailored Post-Session DCSPre-Session DCSPlaceboNon-Tailored Post-Session DCSTotal
Hispanic or Latino5610930
Not Hispanic or Latino33322625116
Unknown or Not Reported20226
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tailored Post-Session DCSPre-Session DCSPlaceboNon-Tailored Post-Session DCSTotal
American Indian or Alaska Native00000
Asian6781334
Native Hawaiian or Other Pacific Islander00000
Black or African American854320
White2523241890
More than one race01225
Unknown or Not Reported12003
Region of Enrollment
Region of Enrollment(participants)Tailored Post-Session DCSPre-Session DCSPlaceboNon-Tailored Post-Session DCSTotal
United States40383836152
08

Study locations

3 sites
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Boston University
    Boston, Massachusetts 02215, United States
  • University of Texas at Austin
    Austin, Texas 78712, United States
09

References and documents

Publications

  • Taylor CT, Rosenfield D, Dowd SM, Dutcher CD, Hofmann SG, Otto MW, Pollack MH, Smits JAJ. What good are positive emotions for treatment? A replication test of whether trait positive emotionality predicts response to exposure therapy for social anxiety disorder. Behav Res Ther. 2023 Dec;171:104436. doi: 10.1016/j.brat.2023.104436. Epub 2023 Nov 11. PubMed 37979218 ↗
  • Lubin RE, Fitzgerald HE, Rosenfield D, Carpenter JK, Papini S, Dutcher CD, Dowd SM, Hofmann SG, Pollack MH, Smits JAJ, Otto MW. Using pre-treatment de novo threat conditioning outcomes to predict treatment response to DCS augmentation of exposure-based CBT. J Psychiatr Res. 2023 Aug;164:357-363. doi: 10.1016/j.jpsychires.2023.06.008. Epub 2023 Jun 19. PubMed 37399757 ↗
  • Dutcher CD, Dowd SM, Zalta AK, Taylor DJ, Rosenfield D, Perrone A, Otto MW, Pollack MH, Hofmann SG, Smits JAJ. Sleep quality and outcome of exposure therapy in adults with social anxiety disorder. Depress Anxiety. 2021 Nov;38(11):1182-1190. doi: 10.1002/da.23167. Epub 2021 May 19. PubMed 34010494 ↗
  • Smits JAJ, Pollack MH, Rosenfield D, Otto MW, Dowd S, Carpenter J, Dutcher CD, Lewis EM, Witcraft SM, Papini S, Curtiss J, Andrews L, Kind S, Conroy K, Hofmann SG. Dose Timing of D-Cycloserine to Augment Exposure Therapy for Social Anxiety Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2020 Jun 1;3(6):e206777. doi: 10.1001/jamanetworkopen.2020.6777. PubMed 32496566 ↗
  • Hofmann SG, Papini S, Carpenter JK, Otto MW, Rosenfield D, Dutcher CD, Dowd S, Lewis M, Witcraft S, Pollack MH, Smits JAJ. Effect of d-cycloserine on fear extinction training in adults with social anxiety disorder. PLoS One. 2019 Oct 17;14(10):e0223729. doi: 10.1371/journal.pone.0223729. eCollection 2019. PubMed 31622374 ↗
  • Hofmann SG, Carpenter JK, Otto MW, Rosenfield D, Smits JA, Pollack MH. Dose timing of D-cycloserine to augment cognitive behavioral therapy for social anxiety: Study design and rationale. Contemp Clin Trials. 2015 Jul;43:223-30. doi: 10.1016/j.cct.2015.06.015. Epub 2015 Jun 23. PubMed 26111923 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2014 to primary completion in Jul 2018, 51 months.

Results were first posted in Jun 2020, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2014
First posted
Feb 20, 2014
StartActual
Apr 2014
Primary completionActual
Jul 1, 2018
CompletionActual
Jul 1, 2018
Results first posted
Jun 9, 2020
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02066792
Lead sponsor
Jasper A. Smits
Collaborators
Rush University Medical Center, Boston University, Southern Methodist University
Responsible party
Jasper A. Smits (Principal Investigator, University of Texas at Austin) — Sponsor-investigator
First posted
Feb 20, 2014
Start date
Apr 2014
Primary completion
Jul 1, 2018
Completion
Jul 1, 2018
Results posted
Jun 9, 2020
Last update
Jun 15, 2026

Study contacts

Mark Pollack, M.D.
principal investigator · Rush University Medical Center
Stefan Hofmann, Ph.D.
principal investigator · Boston University
Jasper A Smits, Ph.D.
principal investigator · University of Texas at Austin

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cycloserine

Start the discussion